Product Name:

NebuPeptide™ Eptifibatide (Peptide Reference)

Catalog Number:

NBS-233796

Description:

NebuPeptide™ Eptifibatide (Peptide Reference)(CAT#NBS-233796) is synthesized in accordance with the Eptifibatide sequence and can be utilized for a variety of in vivo and in vitro studies, including quality control, bioactivity verification, immunization, drug development, structural analysis, etc. Nebula Biotechnology Co., Ltd. is capable of providing Ganirelix Acetate reference peptide ranging from milligrams to kilograms.

Peptide Name:

Eptifibatide

Background:

Eptifibatide is a potent glycoprotein IIb/IIIa antagonist (GPIIb/IIIa; Kd = 120 nM) that inhibits platelet aggregation. Eptifibatide prevents binding of the adhesion proteins fibrinogen and von Willebrand factor to GPIIb/IIIa on the surface of activated platelets to prevent aggregation and thrombus formation. It inhibits ADP-induced citrated blood aggregation (IC50 = 0.11-0.22 μg/ml) in vitro and in vivo (IC50 = 52 μg/ml in porcine plasma). Formulations containing eptifibatide have been used to reduce risk of thrombolysis in myocardial infarction in patients undergoing percutaneous coronary intervention.

Alias:

N/A

CAS Number:

188627-80-7

Formula:

C35H49N11O9S2

Molecular Weight:

831.96

Purity:

see COA

Solubility:

see COA

Storage & Shipment:

Store at -20℃; ship with blue ice.

For R&D use only!

To get more information, please contact us freely.